Ibrance Trial Cements CDK4/6 Inhibitors As Standard Of Care In Breast Cancer

New England Journal of Medicine editorial sings the praises of CDK4/6 inhibitors in breast cancer, which include Pfizer's Ibrance, Novartis's ribociclib and Elli Lilly's abemaciclib.